Vernal Keratoconjunctivitis's Fourth Consecutive Spring: Cumulative Steroid Exposure in a Growing Child
A fourth spring, a fourth flare, and the question of whether repeating last year's plan is still the right default.
Omar T., an 8-year-old boy, is in his fourth consecutive spring of intense bilateral eye itching, thick ropy discharge, photophobia severe enough to keep him from outdoor recess, and the characteristic giant papillae under his upper eyelids that his ophthalmologist has confirmed on slit-lamp exam each of the past three years as vernal keratoconjunctivitis. Each spring he has received a short topical corticosteroid course — loteprednol, tapered over four to six weeks — with reliable symptom resolution each time, only for the disease to recur predictably the following season. This is now his fourth such course in four years, and today's visit opens with the ophthalmologist raising the cumulative-exposure question directly, before even examining him.
Vernal keratoconjunctivitis is itself an uncommon, predominantly pediatric, warm-climate-associated disease, and this degree of clean yearly recurrence with reliable steroid response, while consistent with a straightforward VKC course, is enough of a pattern that his allergist wants to confirm nothing has been missed before simply repeating last year's plan — a corneal exam today confirms no shield ulcer or other vision-threatening complication, and his conjunctival scrapings show the eosinophil-predominant picture typical of VKC rather than anything atypical. With the diagnosis and disease course confirmed rather than assumed, the actual treatment question becomes whether a fourth consecutive corticosteroid course is still the right default, or whether the pediatric trial evidence for topical calcineurin inhibitors now argues for a genuine steroid-sparing switch. That evidence is not symmetrical between the two agents usually named together: cyclosporine has a randomized, vehicle-controlled pediatric VKC trial behind it — VEKTIS (Leonardi et al., 2019) enrolled 169 children aged 4 to 17 with severe VKC, which brackets Omar at 8 — while topical tacrolimus rests on smaller and less rigorously controlled work in the same disease.
Omar has no other chronic medical conditions, and his family recently noted that his symptoms seem worse during unusually hot, dry stretches of weather, consistent with the known association between vernal keratoconjunctivitis and warm climates, though the family lives in a temperate region and his flares have occurred reliably each spring regardless of that particular year's weather pattern. He has never required emergency treatment for his eyes and has maintained normal vision throughout — which is exactly what makes this year's decision harder than the last three. There is no complication to point to, no threshold he has crossed, nothing to show the family; the only thing that has changed since last spring is the number four, and the group has to decide whether a count alone is grounds for abandoning something that has worked every time.
Repeating a working plan, or breaking a pattern
This is his fourth consecutive year, and it would be his fourth consecutive corticosteroid course. That's exactly the cumulative-exposure pattern where I'd want to move to a genuine steroid-sparing agent — cyclosporine has real pediatric trial evidence specifically in VKC rather than borrowed adult data — VEKTIS randomized 169 children in his exact age band against vehicle. I'd hold tacrolimus back as the second-line of the two; its VKC evidence is thinner, whatever the class label suggests.
The steroid course has worked reliably for him every single year, with no complications we've seen in him. The calcineurin-inhibitor evidence base is real but considerably smaller, and both drugs carry a real local burning sensation — worse with tacrolimus, which is also the one you've just conceded has the weaker evidence — that could genuinely hurt adherence in an 8-year-old.
I don't think a track record this clean in him specifically should be abandoned just because a newer option exists on paper.
Before either of you, I wanted to make sure we weren't just repeating last year's plan without re-checking the case — this degree of clean yearly recurrence is uncommon enough that it was worth confirming nothing atypical was going on. Today's corneal exam and scrapings did that; this is straightforward VKC, not something rarer wearing its costume.
With that settled, I'd side with the cumulative-exposure argument. Local burning is a real, manageable tolerability issue we can watch for directly. A fourth consecutive year of topical ocular corticosteroid is the bigger cumulative concern between the two options — and to be precise about what that risk actually is, it's local: intraocular pressure elevation and cataract with repeated courses, not the systemic growth suppression a parent hears in the word 'steroid.'
Agreed, once the diagnostic re-check was complete: start tacrolimus ointment as a steroid-sparing switch for this season, with close early follow-up specifically to catch tolerability issues before they affect adherence.
The disagreement that preceded this agreement was resolved by evidence, not compromise — the pediatrician's concern about tolerability was heard and built into the follow-up plan directly, but the cumulative-exposure argument, once the diagnosis was independently reconfirmed rather than assumed, carried the day for all three.